Skip to content

Functional Magnetic Resonance Imaging for High Throughput Curietherapy Planning in Prostate Cancer

Functional Magnetic Resonance Imaging for High Throughput Curietherapy Planning in Prostate Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02516995
Acronym
FIBROP
Enrollment
10
Registered
2015-08-06
Start date
2010-08-31
Completion date
2014-07-31
Last updated
2016-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Brief summary

Merge the data of ultrasound with that of the anatomical and functional MRI is necessary since the high dose rate Curietherapy is carried out under ultrasound guidance. The investigators will recruit prostate cancer patients to evaluate the quality of the data, their sensitivity to exam conditions (patient position, volume of endorectal probe, gold grains implanted before intensity modulated radiotherapy , IMRT) and to merge data from different sources with the purpose of estimating the opportunities of integration treatment plan for Curietherapy broadband. The nuclear magnetic resonance imaging provides precise anatomical study, but also provides access to a functional approach to the tumor mapping of water diffusion coefficient (DW-MRI), for dynamic imaging with injection contrast agent (DCE-MRI) and finally by spectroscopic imaging (IRMS). This multimodality imaging project is part of a multidisciplinary context, involving close collaboration between clinicians, medical physicists, and physicists of the teams participating in this project (Institut Gustave Roussy and U2R2M-CIERM hospital Kremlin-Bicetre).

Interventions

DEVICEFunctional magnetic resonance imaging
DEVICEUltrasound

Sponsors

Gustave Roussy, Cancer Campus, Grand Paris
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

Patients with prostate cancer biopsy-proven, intermediate or high risk (according to D'Amico Classification), for which radiotherapy is indicated. * Accepting the imaging tests. * Age \<70 years. * Informed consent signed.

Exclusion criteria

* Mental pathology that can interfere with the proper conduct of the study; * Claustrophobia; * Severe heart or respiratory disorder that can make it difficult to achieve relatively long imaging tests * Contraindications to magnetic resonance imaging (MRI) 1. pacemaker, other electronic appliance (depending on model); 2. heart valve, intra-cranial clip aneurysm, cerebral ventricular bypass valve (depending on model); 3. intraocular metallic foreign bodies (chips), and other locations, according to the site to discuss. 4. metal tracheostomy cannula; 5. endovascular stent or vascular embolization coils placed within six weeks in advance; 6. the impediments to a long examination with spectroscopy sequence of ten to twenty minutes: major tremors, inability to lie more than 30 minutes; 7. local sources of magnetic distortion which is sensitive spectroscopic imaging: hip replacement, prostate biopsy older than six weeks.

Design outcomes

Primary

MeasureTime frame
Quality of imaging [good/good enough/not good enough]Assessed six weeks after inclusion

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026